Certara/$CERT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Certara

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Ticker

$CERT
Primary listing

Industry

Health Care Technology

Employees

1,517

ISIN

US15687V1098

Certara Metrics

BasicAdvanced
$1.9B
-
-$0.02
1.45
-

What the Analysts think about Certara

Analyst ratings (Buy, Hold, Sell) for Certara stock.

Bulls say / Bears say

Barclays upgraded Certara's stock rating from 'Equal Weight' to 'Overweight' and increased the price target to $14.00, citing strong performance and potential acceleration in business performance in the latter half of the year. (Investing.com)
Certara reported preliminary Q1 2025 revenue of $106 million, a 10% year-over-year increase, exceeding analyst expectations and demonstrating robust financial performance. (TradingView News)
The company authorized a $100 million share repurchase program, indicating confidence in its financial health and commitment to returning value to shareholders. (TradingView News)
Barclays downgraded Certara's price target from $13.00 to $11.00, maintaining an 'Equal Weight' rating due to concerns over market uncertainties and potential budget constraints in the life sciences sector. (GuruFocus News)
Leerink Partners reduced their FY2027 earnings per share estimates for Certara, reflecting a weaker outlook for the company's long-term profitability. (ETF Daily News)
Certara's stock experienced significant volatility, with a 22.84% surge following the release of a new version of its Simcyp Simulator, indicating potential instability in investor sentiment. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

Certara Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Certara Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CERT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs